134 related articles for article (PubMed ID: 38671586)
21. Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
Conde K; Roy S; Freake HC; Newton RS; Fernandez ML
Lipids; 1999 Dec; 34(12):1327-32. PubMed ID: 10652993
[TBL] [Abstract][Full Text] [Related]
22. Waldenström macroglobulinaemia: the key questions.
D'Souza A; Ansell S; Reeder C; Gertz MA
Br J Haematol; 2013 Aug; 162(3):295-303. PubMed ID: 23651417
[TBL] [Abstract][Full Text] [Related]
23. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
24. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Qin J; Zhang Z; Liu J; Sun L; Hu L; Cooper ME; Cao Z
Kidney Int; 2003 Aug; 64(2):565-71. PubMed ID: 12846751
[TBL] [Abstract][Full Text] [Related]
25. Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes.
Bonn V; Cheung RC; Chen B; Taghibiglou C; Van Iderstine SC; Adeli K
Atherosclerosis; 2002 Jul; 163(1):59-68. PubMed ID: 12048122
[TBL] [Abstract][Full Text] [Related]
26. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
27. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors.
Gerson RJ; MacDonald JS; Alberts AW; Chen J; Yudkovitz JB; Greenspan MD; Rubin LF; Bokelman DL
Exp Eye Res; 1990 Jan; 50(1):65-78. PubMed ID: 2307197
[TBL] [Abstract][Full Text] [Related]
28. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
Saheki A; Terasaki T; Tamai I; Tsuji A
Pharm Res; 1994 Feb; 11(2):305-11. PubMed ID: 8165193
[TBL] [Abstract][Full Text] [Related]
29. Simvastatin-induced lactic acidosis: a rare adverse reaction?
Goli AK; Goli SA; Byrd RP; Roy TM
Clin Pharmacol Ther; 2002 Oct; 72(4):461-4. PubMed ID: 12386648
[TBL] [Abstract][Full Text] [Related]
30. Waldenström macroglobulinaemia presenting as tingling ulcers on the feet.
Fischer I; Dyall-Smith D; Peters B; Stolz W; Coras-Stepanek B
Dermatol Pract Concept; 2013; 3(3):7-8. PubMed ID: 24106654
[TBL] [Abstract][Full Text] [Related]
31. HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS.
Seker FB; Kilic U; Caglayan B; Ethemoglu MS; Caglayan AB; Ekimci N; Demirci S; Dogan A; Oztezcan S; Sahin F; Yilmaz B; Kilic E
Neuroscience; 2015 Jan; 284():349-359. PubMed ID: 25453767
[TBL] [Abstract][Full Text] [Related]
32. The protective effect of simvastatin against low dose streptozotocin induced type 1 diabetes in mice is independent of inhibition of HMG-CoA reductase.
Rydgren T; Sandler S
Biochem Biophys Res Commun; 2009 Feb; 379(4):1076-9. PubMed ID: 19150339
[TBL] [Abstract][Full Text] [Related]
33. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.
Gustine JN; Meid K; Dubeau T; Hunter ZR; Xu L; Yang G; Ghobrial IM; Treon SP; Castillo JJ
Br J Haematol; 2017 Jun; 177(5):717-725. PubMed ID: 28485115
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin.
Atil B; Berger-Sieczkowski E; Bardy J; Werner M; Hohenegger M
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jan; 389(1):17-32. PubMed ID: 26319048
[TBL] [Abstract][Full Text] [Related]
35. Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography.
Hosokawa R; Nohara R; Linxue L; Tamaki S; Hashimoto T; Tanaka M; Miki S; Sasayama S
Jpn Circ J; 2000 Mar; 64(3):177-82. PubMed ID: 10732848
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
37. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
38. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.
Park HJ; Kong D; Iruela-Arispe L; Begley U; Tang D; Galper JB
Circ Res; 2002 Jul; 91(2):143-50. PubMed ID: 12142347
[TBL] [Abstract][Full Text] [Related]
39. TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes.
Lobo SM; Quinto BM; Oyama L; Nakamichi R; Ribeiro AB; Zanella MT; Dalboni MA; Batista MC
Cytokine; 2012 Oct; 60(1):150-6. PubMed ID: 22658637
[TBL] [Abstract][Full Text] [Related]
40. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Nov; 64(5):477-83. PubMed ID: 9834039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
